Notably, miR-199a-3p functions as a tumor suppressor by targeting Rheb and enhances sensitivity to gefitinib (27), while miR-222-3p promotes malignant traits and gemcitabine resistance by targeting SOCS3 (47). Here, RHEB is linked to neoplasm.